Viracta Therapeutics, Inc.
VIRX · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $738 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $96 | $110 | $123 |
| Gross Profit | $0 | -$96 | -$110 | $615 |
| % Margin | – | – | – | 83.3% |
| R&D Expenses | $7,181 | $6,548 | $9,956 | $9,406 |
| G&A Expenses | $3,004 | $3,041 | $3,920 | $4,154 |
| SG&A Expenses | $3,004 | $3,041 | $3,810 | $4,031 |
| Sales & Mktg Exp. | $0 | $0 | -$110 | -$123 |
| Other Operating Expenses | $0 | $0 | $0 | -$7 |
| Operating Expenses | $10,185 | $9,589 | $13,766 | $13,437 |
| Operating Income | -$10,185 | -$9,589 | -$13,876 | -$13,560 |
| % Margin | – | – | – | -1,837.4% |
| Other Income/Exp. Net | -$368 | -$241 | $4,735 | -$204 |
| Pre-Tax Income | -$10,553 | -$9,830 | -$9,141 | -$13,765 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10,553 | -$9,830 | -$9,141 | -$13,765 |
| % Margin | – | – | – | -1,865.2% |
| EPS | -0.27 | -0.25 | -0.23 | -0.35 |
| % Growth | -8% | -8.7% | 34.3% | – |
| EPS Diluted | -0.27 | -0.25 | -0.23 | -0.35 |
| Weighted Avg Shares Out | 39,574 | 39,405 | 39,324 | 38,790 |
| Weighted Avg Shares Out Dil | 39,574 | 39,405 | 39,324 | 38,790 |
| Supplemental Information | – | – | – | – |
| Interest Income | $312 | $457 | $592 | $752 |
| Interest Expense | $679 | $697 | $858 | $949 |
| Depreciation & Amortization | $110 | $96 | $110 | $123 |
| EBITDA | -$9,764 | -$9,037 | -$8,173 | -$12,693 |
| % Margin | – | – | – | -1,719.9% |